Insider trading

Period: 120 months Stock: VRTX + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

738 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

738 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

738 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

738 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
738 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
738 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

738 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
14 Apr 2022
Lee Yuchun Director
Sold, plan not stated 4×
$578.12K 2,000 at 289.06
51.6%
Sold half or more
13 Apr 2022
LEIDEN JEFFREY M Executive Chairman
Sold, plan not stated
$4.56M 15,789 at 289.04
17.6%
13 Apr 2022
Lee Yuchun Director
Sold, plan not stated 8×
$575.01K 2,000 at 287.50
51.6%
Sold half or more
12 Apr 2022
Lee Yuchun Director
Sold, plan not stated 4×
$562.05K 2,000 at 281.03
51.6%
Sold half or more
11 Apr 2022
Lee Yuchun Director
Sold, plan not stated 3×
$560.60K 2,000 at 280.30
51.6%
Sold half or more
8 Apr 2022
Sold, plan not stated 2×
$1.40M 5,000 at 280.22
82.0%
Sold half or more
8 Apr 2022
Lee Yuchun Director
Sold, plan not stated 4×
$557.14K 2,000 at 278.57
51.6%
Sold half or more
8 Apr 2022
Sold, plan not stated
$534.34K 1,907 at 280.20
26.9%
7 Apr 2022
Lee Yuchun Director
Sold, plan not stated 5×
$549.72K 2,000 at 274.86
51.6%
Sold half or more
7 Apr 2022
Sanna Bastiano EVP, Cell & Genetic Therapies
Sold, plan not stated 3×
$154.93K 561 at 276.18
1.3%
6 Apr 2022
Lee Yuchun Director
Sold, plan not stated 4×
$543.24K 2,000 at 271.62
51.6%
Sold half or more
5 Apr 2022
Sanna Bastiano EVP, Cell & Genetic Therapies
Sold, plan not stated
$870.55K 3,163 at 275.23
6.8%
5 Apr 2022
Lee Yuchun Director
Sold, plan not stated 6×
$544.99K 2,000 at 272.50
51.6%
Sold half or more
4 Apr 2022
Lee Yuchun Director
Sold, plan not stated 3×
$535.43K 2,000 at 267.72
51.6%
Sold half or more
4 Apr 2022
Sanna Bastiano EVP, Cell & Genetic Therapies
Sold, plan not stated 2×
$150.45K 562 at 267.71
1.2%
1 Apr 2022
WAGNER CHARLES F JR EVP & Chief Financial Officer
Sold, plan not stated 5×
$683.60K 2,582 at 264.76
5.6%
31 Mar 2022
Sold, plan not stated 3×
$1.31M 5,000 at 262.27
82.0%
Sold half or more
17 Mar 2022
WAGNER CHARLES F JR EVP & Chief Financial Officer
Sold, plan not stated 2×
$793.22K 3,171 at 250.15
6.4%
17 Mar 2022
Tatsis Ourania EVP, Chief Reg. & Quality Off.
Sold, plan not stated 2×
$708.57K 2,833 at 250.11
5.6%
17 Mar 2022
Sanna Bastiano EVP, Cell & Genetic Therapies
Sold, plan not stated
$530.63K 2,122 at 250.06
4.2%
25 Feb 2022
ALTSHULER DAVID EVP, Global Research and CSO
Sold, plan not stated 4×
$1.75M 7,572 at 230.98
17.3%
25 Feb 2022
Tatsis Ourania EVP, Chief Reg. & Quality Off.
Sold, plan not stated 5×
$75.06K 325 at 230.95
0.6%
18 Feb 2022
ALTSHULER DAVID EVP, Global Research and CSO
Sold, plan not stated 5×
$995.95K 4,312 at 230.97
8.0%
18 Feb 2022
Tatsis Ourania EVP, Chief Reg. & Quality Off.
Sold, plan not stated 4×
$119.89K 519 at 231.00
1.0%
14 Feb 2022
ALTSHULER DAVID EVP, Global Research and CSO
Sold, plan not stated
$567.06K 2,444 at 232.02
4.1%
11 Feb 2022
ALTSHULER DAVID EVP, Global Research and CSO
Sold, plan not stated 4×
$539.84K 2,297 at 235.02
3.7%
11 Feb 2022
Tatsis Ourania EVP, Chief Reg. & Quality Off.
Sold, plan not stated 4×
$68.18K 290 at 235.09
0.5%
2 Feb 2022
ALTSHULER DAVID EVP, Global Research and CSO
Sold, plan not stated 7×
$1.17M 4,660 at 251.47
6.6%
2 Feb 2022
WAGNER CHARLES F JR EVP & Chief Financial Officer
Sold, plan not stated
$736.21K 2,944 at 250.07
4.9%
2 Feb 2022
Sanna Bastiano EVP, Cell & Genetic Therapies
Sold, plan not stated 5×
$261.02K 1,040 at 250.98
1.9%
28 Jan 2022
Sold, plan not stated 4×
$1.21M 5,000 at 241.79
82.0%
Sold half or more
15 Nov 2021
Sachdev Amit EVP, Chief Patient Officer
Sold, plan not stated 2×
$9.55K 51 at 187.19
0.2%
15 Nov 2021
ALTSHULER DAVID EVP, Global Research and CSO
Sold, plan not stated 2×
$6.37K 34 at 187.22
0.1%
15 Nov 2021
Sold, plan not stated 2×
$561.78 3 at 187.26
0.0%
19 Aug 2021
Kewalramani Reshma CEO & President
Bought 2×
$1.96M 10,000 at 195.65
15.7%
First buy on file
2 Aug 2021
SACHS BRUCE I Director
Bought
$2.97M 15,000 at 197.91
57.2%
+57% of stake
2 Jun 2021
Sold, plan not stated 3×
$117.22K 559 at 209.69
9.7%
17 May 2021
Liu Joy SVP, General Counsel
Sold, plan not stated 2×
$24.23K 112 at 216.34
1.3%
17 May 2021
Sanna Bastiano EVP, Cell & Genetic Therapies
Sold, plan not stated 2×
$24.23K 112 at 216.34
0.3%
17 May 2021
Arbuckle Stuart A EVP, Chief Comm & Ops Officer
Sold, plan not stated 3×
$23.59K 109 at 216.41
0.3%
17 May 2021
ALTSHULER DAVID EVP, Global Research and CSO
Sold, plan not stated 3×
$17.09K 79 at 216.36
0.2%
17 May 2021
Sachdev Amit EVP, Chief Patient Officer
Sold, plan not stated 3×
$9.74K 45 at 216.35
0.1%
3 May 2021
Sanna Bastiano EVP, Cell & Genetic Therapies
Sold, plan not stated 2×
$209.69K 960 at 218.43
2.7%
27 Apr 2021
Sachdev Amit EVP, Chief Patient Officer
Sold, plan not stated 3×
$839.19K 3,884 at 216.06
8.8%
5 Apr 2021
Sanna Bastiano EVP, Cell & Genetic Therapies
Sold, plan not stated 2×
$361.05K 1,686 at 214.14
4.5%
5 Mar 2021
Liu Joy SVP, General Counsel
Sold, plan not stated 6×
$1.08M 5,141 at 209.69
38.4%
1 Mar 2021
Silva Paul M SVP & Chief Accounting Officer
Sold, plan not stated 4×
$588.26K 2,782 at 211.45
22.0%
25 Feb 2021
Arbuckle Stuart A EVP, Chief Commercial Officer
Sold, plan not stated 6×
$775.99K 3,634 at 213.54
8.1%
25 Feb 2021
Sachdev Amit EVP, Chief Patient Officer
Sold, plan not stated 5×
$765.31K 3,586 at 213.42
8.2%
25 Feb 2021
ALTSHULER DAVID EVP, Global Research and CSO
Sold, plan not stated 4×
$646.14K 3,028 at 213.39
8.3%
Showing 251–300 of 738. ← Newer Page 6 of 15 Older →